CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, announced today that Geno Germano has been appointed to Sage’s Board of Directors.
“The Sage team is excited to welcome Mr. Germano to our Board,” said Jeff Jonas, M.D., Chief Executive Officer of Sage. “Mr. Germano’s clear passion for creating medicines that significantly improve patients’ lives is a perfect fit with Sage’s vision and culture.
“The Sage team is excited to welcome Mr. Germano to our Board,” said Jeff Jonas, M.D., Chief Executive Officer of Sage. “Mr. Germano’s clear passion for creating medicines that significantly improve patients’ lives is a perfect fit with Sage’s vision and culture.
